Last reviewed · How we verify

NanoFlu — Competitive Intelligence Brief

NanoFlu (NanoFlu) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant nanoparticle vaccine. Area: Immunology / Infectious Disease.

phase 3 Recombinant nanoparticle vaccine Influenza hemagglutinin (HA) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

NanoFlu (NanoFlu) — Novavax. NanoFlu is a recombinant nanoparticle-based influenza vaccine that displays hemagglutinin proteins on virus-like particles to stimulate robust immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NanoFlu TARGET NanoFlu Novavax phase 3 Recombinant nanoparticle vaccine Influenza hemagglutinin (HA)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant nanoparticle vaccine class)

  1. Novavax · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NanoFlu — Competitive Intelligence Brief. https://druglandscape.com/ci/nanoflu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: